Sotera Health Executive Compensation (FY25)
SHC · Executive and director compensation, fiscal 2024 to 2025
The Sotera Health brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
Data as of September 21, 2026Latest filing (8-K): May 22, 2026
6 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
$1,500Get the executive brief
230 figures on this page: 226 cited to the filing that reported them, 4 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Michael Petras: $10,392,468 → $10,656,063 (2.5% higher)
CEO pay ratio: 136:1 → 129:1 (5.1% lower)
Frequently asked questions
Answers drawn from the data on this page.
Who is Sotera Health's chief executive and what were they paid?
Michael Petras was paid $10,656,063 in total compensation as Chairman and CEO for fiscal 2025. Petras' total moved 2.5% higher from the $10,392,468 reported for fiscal 2024.
What was Sotera Health's say-on-pay result?
The say-on-pay proposal drew 97.5% support at the meeting held May 21, 2026 for fiscal 2025.
Which companies are in Sotera Health's peer group?
Companies named in the disclosed peer group include Avanos Medical, Inc., Bio-Techne Corporation, CONMED Corporation, Haemonetics Corporation and Hologic, Inc., among others.
What is Sotera Health's chief executive pay ratio?
The company reported a chief executive pay ratio of 129:1 for fiscal 2025, against median employee compensation of $82,784.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Michael Petras Chairman and CEO | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Michael Rutz President of Sterigenics | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Alexander Dimitrief SVP and General Counsel | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Jonathan Lyons Senior Vice President, Chief Financial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Michael Petras Chairman and CEO | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Jonathan Lyons Senior Vice President, Chief Financial Officer | ◇ | ◇ | ◇ | — | ◇ | — | ◇ | ◇ |
Alexander Dimitrief Former SVP and General Counsel Departed during or after this year | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Michael Rutz President of Sterigenics | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Alexander Dimitrief | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Alexander Dimitrief | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Alexander Dimitrief | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Jonathan Lyons | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Jonathan Lyons | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Jonathan Lyons | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Jonathan Lyons | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Michael B. Petras Jr | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Michael B. Petras Jr | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Michael B. Petras Jr | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Michael P. Rutz | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Michael P. Rutz | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Michael P. Rutz | RSU | ◇ | — | — | ◇ | — | — | ◇ |
Fiscal 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Jonathan Lyons | Option | ◇ | — | ◇ | — |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Alexander Dimitrief | Option | ◇ | — | ◇ | — |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Michael Petras | Option | ◇ | — | ◇ | — |
| Option | ◇ | — | ◇ | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| Michael Rutz | PSU | ◇ | ◇ | — | — |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Severance and change in control
The terms as written in the agreements.
Alexander Dimitrief
Former SVP and General Counsel · Terms as described in the company’s compensation discussion · citing a 2026 filing
| Equity acceleration on change in control | ◇ |
Jonathan Lyons
Senior Vice President, Chief Financial Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
| Severance multiple | ◇ |
| Severance cash amount | ◇ |
| Change-in-control multiple | ◇ |
Michael Petras
Chairman and CEO · Terms as described in the company’s compensation discussion · citing a 2026 filing
| Severance multiple | ◇ |
| Severance base | ◇ |
| Severance cash amount | ◇ |
| Change-in-control multiple | ◇ |
| Change-in-control base | ◇ |
| Equity acceleration on change in control | ◇ |
| Benefits continuation on change in control | ◇ |
| Benefits continuation | ◇ |
Michael Rutz
President of Sterigenics · Terms as described in the company’s compensation discussion · citing a 2026 filing
| Severance multiple | ◇ |
| Severance base | ◇ |
| Severance cash amount | ◇ |
| Change-in-control multiple | ◇ |
| Change-in-control base | ◇ |
| Benefits continuation on change in control | ◇ |
| Benefits continuation | ◇ |
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Vincent K. Petrella Lead independent director | ◇ | ◇ | — | — | — | — | ◇ |
Christopher A. Simon | ◇ | ◇ | — | — | — | — | ◇ |
Sean L. Cunningham | ◇ | ◇ | — | — | — | — | ◇ |
Ann R. Klee | ◇ | ◇ | — | — | — | — | ◇ |
James C. Neary | ◇ | ◇ | — | — | — | — | ◇ |
David E. Wheadon, M.D | ◇ | ◇ | — | — | — | — | ◇ |
David E. Wheadon | ◇ | ◇ | — | — | — | — | ◇ |
Karen A. Flynn | ◇ | ◇ | — | — | — | — | ◇ |
Constantine S. Mihas | ◇ | ◇ | — | — | — | — | ◇ |
Ruoxi Chen | ◇ | ◇ | — | — | — | — | ◇ |
Robert B. Knauss | ◇ | ◇ | — | — | — | — | ◇ |
Richard G. Kyle, Michael B. Petras Jr, Kenneth D. Krause and David A. Donnini served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Lead independent director premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Equity is delivered as restricted stock units.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- Avanos Medical, Inc. AVNS
- Bio-Techne Corporation TECH
- CONMED Corporation CNMD
- Haemonetics Corporation HAE
- Hologic, Inc. HOLX
- Integra LifeSciences Holdings Corporation IART
- Maravai LifeSciences Holdings, Inc. MRVI
- Masimo Corporation MASI
- Medpace Holdings, Inc. MEDP
- Merit Medical Systems, Inc. MMSI
- QuidelOrtho Corporation QDEL
- Repligen Corporation RGEN
- ResMed Inc. RMD
- STERIS plc STE
- Tandem Diabetes Care, Inc. TNDM
- Teleflex Incorporated TFX
- The Cooper Companies, Inc. COO
- Waters Corporation WAT
- West Pharmaceutical Services, Inc. WST
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | May 21, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | May 21, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | May 23, 2024 | = | ◇ | ◇ | ◇ |
| 2022 | May 25, 2023 | = | ◇ | ◇ | ◇ |
Chief executive pay ratio
As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
What this page does not include
Everything above is a fact Sotera Health disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Sotera Health sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
230 figures on this page: 226 cited to the filing that reported them, 4 calculated from figures it prints.
226 cited to the filing
4 calculated from the filing
Documents cited
- 0001822479-26-000034Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001104659-26-0409372025 Director Compensation Table · 2025 Grants of Plan-Based Awards · 2025 Summary Compensation Table · CEO PAY RATIO · and 3 more sections
- 0001822479-25-000028Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001104659-25-0335632024 Summary Compensation Table
- 0001822479-24-000027
- 0001822479-23-000037
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Sotera Health executive compensation, FY2024–FY2025.” https://intel.velarion.ai/comp/SHC (accessed 2026).
Short form: data: Velarion
The Sotera Health brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
6 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Sotera Health and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Peers Sotera Health discloses
The companies named in SHC's own disclosed peer group.
Avanos Medical, Inc.Bio-Techne CorporationCONMED CorporationHaemonetics CorporationHologic, Inc.Integra LifeSciences Holdings CorporationMaravai LifeSciences Holdings, Inc.Masimo CorporationMedpace Holdings, Inc.Merit Medical Systems, Inc.QuidelOrtho CorporationRepligen CorporationResMed Inc.STERIS plcTandem Diabetes Care, Inc.Teleflex IncorporatedThe Cooper Companies, Inc.Waters CorporationWest Pharmaceutical Services, Inc.
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}